PHOENIX, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Phoenix, Feb. 11th, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (the “Company”), a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. President and CEO, Phil Deschamps, joined Stock Day host Everett Jolly to discuss their clearance in Canada and share the progress of their expansion into the United States, Europe and Australia.
Jolly began the interview by asking Deschamps to share with listeners what the Company specializes in. Deschamps explained, “We are a company that is dedicated to the treatment of neurological symptoms of disease or trauma. What does that mean? We help to treat the symptoms of things like traumatic brain injury, MS, stroke, and cerebral palsy.”
Deschamps further explained that the Company is in the process of developing a technology called PoNS, which is a non-invasive medical device that, initially, aids in the treatment of traumatic brain injuries. PoNS stands for Portable Neuromodulation Stimulator, and stimulates the patient’s tongue to send impulses to the back of the brain. When paired with exercise, like physical therapy, this combination allows the brain to rehabilitate itself and ease the symptoms caused by disease or trauma.
Jolly then inquired about any recent partnerships made by the Company since their last appearance on the show. Deschamps shared that the Company has developed a clinic system throughout Canada that will allow them to offer both the medical device aspect of the treatment program, as well as the physical therapy side of the treatment. “Every time a patient gets treated, we get a transfer payment into the Company. So, that’s the business model that we are adopting in Canada.”
Deschamps then shared that after clearing Canadian regulations, they are approaching the launch of their clinics and accompanying treatments. In fact, the Company is expecting revenues for the first quarter of 2019. As a formerly pre-revenue company, this is exciting news.
Deschamps explained that the Company’s PoNS device and treatment is currently only licensed in Canada, however they are in the process of expanding into both the United States, Europe and Australia.
To close the interview, Deschamps shared that the Company is eager to expand their non-invasive technology to treat a greater number of conditions, and shared his excitement for the Company’s future.
To hear the entire interview with Phil Deschamps, listen to the podcast here: https://upticknewswire.com/featured-interview-ceo-phillipe-deschamps-of-helius-medical-technologies-inc-nasdaq-hsdt/
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Treatment
The Portable Neuromodulation Stimulator (PoNS) is an investigational, non-invasive, medical device in the United States, for which Helius has requested De Novo classification and 510(k) clearance from the Food and Drug Administration for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury when combined with targeted physical therapy. PoNS is a licensed class II medical device in Canada. PoNS is currently not commercially available in the United States or the European Union.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
443-213-0500
investorrelations@heliusmedical.com
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Uptick Newswire
602-441-3474
https://upticknewswire.com/